Tofacitinib in Vitiligo: Case Series and Open-Label Studies ± NB-UVB
Key Takeaways Tofacitinib (JAK1/3 inhibitor) has shown facial repigmentation in multiple case series; responses improve with concurrent light (NB-UVB or […]
T-VASI
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V2 Phase 3 Results
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 Phase 3 Results
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued
NB-UVB + Tacrolimus vs NB-UVB Alone in Vitiligo: Randomized Controlled Trial
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many
NB-UVB 311 nm vs PUVA in Vitiligo: Comparative Efficacy and Safety
Key Takeaways NB-UVB achieves comparable or superior facial repigmentation versus PUVA in multiple comparative studies, with fewer systemic adverse effects.
Diagnosis of Vitiligo: Wood’s Lamp, Dermoscopy, Biopsy & Differential Diagnosis
Key Takeaways Clinical diagnosis is usually sufficient; bedside confirmation relies on sharply demarcated depigmentation and accentuation under Wood’s lamp. Dermoscopy
Vitiligo Research Map 1900–2025: Meta-Review, Timeline, and Methods
Key Takeaways Evidence for vitiligo has progressed from descriptive case series to randomized and phase-3 trials; the most mature clinical